Abstract: In order to provide the effective vaccine for the immunoprophylaxis of swine pseudorabies, a genedeleted vaccine against pseudorabies was prepared using a previously constructed mutant, PrV HB-98 (TK^- /gG^- /LacZ⁺ mutant) , that were grown with primary embryo fibroblast cells. The optimal doses for the oral and intramuscular administration of the vaccine were determined, and the safety, efficacy, immunoprotective duration and shelf life of the gene-negative vaccine were measured. In addition, the performances of four batches of the gene-negative vaccine were assessed through field trials, in which the vaccine was clinically applied to sows, piglets and growing pigs in 23 pig farms. The optimal doses of vaccine for oral and intramuscular administration for pigs at different stages were determined to be 10^5.0TCID₅₀. The vaccine was demonstrated to be safe to one-, fifteen-day old piglets and pregnant sows when it was used at dose of 10^6.0TCID₅₀, ten fold of the normal immune dose. The immunized pigs could be protected from challenge with the virulent PrV strain. The vaccine could be stored for six and twelve months under 4℃ and-20℃ respectively without fluctuation of performance. The immunoprotective duration could last for six months in PrV antibody-free commercial and breeding pigs . The highly safety and good efficacy of the vaccine were further confirmed by the results obtained from the field trials, and the vaccine could be used in PrV-suffered piglets to quickly cease the prevalence of Aujeszky's disease. In conclusion, the research provided the useful hints for vaccine production and field applications of the vaccine.